AR and Familial prostate cancer: As an important caveat, we relied upon LNCaP prostate cancer cells for the SARS-CoV-2 bioassay with AR inhibitors, since we were unable to identify a lung epithelial cell line susceptible to SARS-CoV-2 infection that also had adequate AR signaling.